All Stories

  1. Subendocardial Involvement as an Underrecognized Cardiac MRI Phenotype in Myocarditis

    Article • Radiology, January 2022, Radiological Society of North America (RSNA)

    Professor Zhi-Cheng JING

  2. Effect of riociguat on right ventricular function in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension

    Article • The Journal of Heart and Lung Transplantation, October 2021, Elsevier

    Professor Zhi-Cheng JING

  3. Clinical features and survival in Takayasu’s arteritis-associated pulmonary hypertension: a nationwide study

    Article • European Heart Journal, September 2021, Oxford University Press (OUP)

    Professor Zhi-Cheng JING

  4. Identification of Hypoxia Induced Metabolism Associated Genes in Pulmonary Hypertension

    Article • July 2021, Research Square

    Professor Zhi-Cheng JING

  5. Radiofrequency Catheter Ablation of Supraventricular Tachycardia in Patients With Pulmonary Hypertension: Feasibility and Long-Term Outcome

    Article • Frontiers in Physiology, June 2021, Frontiers

    Professor Zhi-Cheng JING

  6. Association Between Anticoagulation Outcomes and Venous Thromboembolism History in Chronic Thromboembolic Pulmonary Hypertension

    Article • Frontiers in Cardiovascular Medicine, May 2021, Frontiers

    Professor Zhi-Cheng JING

  7. Venous thromboembolism in Asia and worldwide: Emerging insights from GARFIELD-VTE

    Article • Thrombosis Research, May 2021, Elsevier

    Professor Zhi-Cheng JING

  8. A Personalized Pulmonary Circulation Model to Non-Invasively Calculate Fractional Flow Reserve for Artery Stenosis Detection

    Article • IEEE Transactions on Biomedical Engineering, January 2021, Institute of Electrical & Electronics Engineers (IEEE)

    Professor Zhi-Cheng JING

  9. DNA methyltransferase 3B deficiency unveils a new pathological mechanism of pulmonary hypertension

    Article • Science Advances, December 2020, American Association for the Advancement of Science

    Professor Zhi-Cheng JING

  10. Association between congenital thrombophilia and outcomes in pulmonary embolism patients

    Article • Blood Advances, December 2020, American Society of Hematology

    Professor Zhi-Cheng JING

  11. Generation of an induced pluripotent stem cell line (PUMCHi006-A) derived from a patient with pulmonary arterial hypertension carrying heterozygous c.1339 G > A mutation in PTGIS gene

    Article • Stem Cell Research, December 2020, Elsevier

    Professor Zhi-Cheng JING

  12. Inflammation and cardiovascular diseases

    Article • Chronic Diseases and Translational Medicine, December 2020, Elsevier

    Professor Zhi-Cheng JING

  13. Alteration of Extracellular Superoxide Dismutase in Idiopathic Pulmonary Arterial Hypertension

    Article • Frontiers in Medicine, November 2020, Frontiers

    Professor Zhi-Cheng JING

  14. The features of rare pathogenic BMPR2 variants in pulmonary arterial hypertension: Comparison between patients and reference population

    Article • International Journal of Cardiology, November 2020, Elsevier

    Professor Zhi-Cheng JING

  15. How should a physician approach the pharmacological management of chronic thromboembolic pulmonary hypertension?

    Article • Expert Opinion on Pharmacotherapy, October 2020, Taylor & Francis

    Professor Zhi-Cheng JING

  16. Effect of ambrisentan on echocardiographic and Doppler measures from patients in China with pulmonary arterial hypertension

    Article • Expert Review of Cardiovascular Therapy, September 2020, Taylor & Francis

    Professor Zhi-Cheng JING

  17. Efficacy and safety of ambrisentan in Chinese patients with connective tissue disease-pulmonary arterial hypertension: a post-hoc analysis

    Article • BMC Cardiovascular Disorders, July 2020, Springer Science + Business Media

    Professor Zhi-Cheng JING

  18. Derivation of an induced pluripotent stem cell line (PUMCHi003-A) from a patient with pulmonary arterial hypertension carrying heterozygous mutation in PTGIS gene

    Article • Stem Cell Research, July 2020, Elsevier

    Professor Zhi-Cheng JING

  19. Cancer associated thrombosis in everyday practice: perspectives from GARFIELD-VTE

    Article • Journal of Thrombosis and Thrombolysis, June 2020, Springer Science + Business Media

    Professor Zhi-Cheng JING

  20. Spermine promotes pulmonary vascular remodelling and its synthase is a therapeutic target for pulmonary arterial hypertension

    Article • European Respiratory Journal, June 2020, European Respiratory Society (ERS)

    Professor Zhi-Cheng JING

  21. Association of Rare PTGIS Variants With Susceptibility and Pulmonary Vascular Response in Patients With Idiopathic Pulmonary Arterial Hypertension

    Article • JAMA Cardiology, June 2020, American Medical Association (AMA)

    Professor Zhi-Cheng JING

  22. Protective effects of isorhamnetin on pulmonary arterial hypertension: in vivo and in vitro studies

    Article • Phytotherapy Research, May 2020, Wiley

    Professor Zhi-Cheng JING

  23. New Insights into the Use of Direct Oral Anticoagulants in Non-high Risk Thrombotic APS Patients: Literature Review and Subgroup Analysis from a Meta-analysis

    Article • Current Rheumatology Reports, May 2020, Springer Science + Business Media

    Professor Zhi-Cheng JING

  24. CSC Expert Consensus on Principles of Clinical Management of Patients With Severe Emergent Cardiovascular Diseases During the COVID-19 Epidemic

    Article • Circulation, May 2020, Wolters Kluwer Health

    Professor Zhi-Cheng JING

  25. Editorial: Drug Development and Target Discovery in Pulmonary Vascular Diseases

    Article • Frontiers in Pharmacology, May 2020, Frontiers

    Professor Zhi-Cheng JING

  26. Challenges and Special Aspects of Pulmonary Hypertension in Middle- to Low-Income Regions

    Article • Journal of the American College of Cardiology, May 2020, Elsevier

    Prof./Phd Ganna D Radchenko, Professor Zhi-Cheng JING

  27. Micro RNA ‐483 amelioration of experimental pulmonary hypertension

    Article • EMBO Molecular Medicine, April 2020, EMBO

    Professor Zhi-Cheng JING

  28. Recommendations from the Peking Union Medical College Hospital for the management of acute myocardial infarction during the COVID-19 outbreak

    Article • European Heart Journal, March 2020, Oxford University Press (OUP)

    Professor Zhi-Cheng JING

  29. The Key Laboratory of Pulmonary Vascular Medicine, Chinese Academy of Medical Sciences (KLPVM-CAMS)

    Article • European Heart Journal, December 2019, Oxford University Press (OUP)

    Professor Zhi-Cheng JING

  30. Protective effects of 18β-glycyrrhetinic acid on pulmonary arterial hypertension via regulation of Rho A/Rho kinsase pathway

    Article • Chemico-Biological Interactions, September 2019, Elsevier

    Professor Zhi-Cheng JING

  31. Association Between High FSH, Low Progesterone, and Idiopathic Pulmonary Arterial Hypertension in Women of Reproductive Age

    Article • American Journal of Hypertension, August 2019, Oxford University Press (OUP)

    Professor Zhi-Cheng JING

  32. Lipocalin-2 Predicts Long-Term Outcome of Normotensive Patients with Acute Pulmonary Embolism

    Article • Cardiovascular Toxicology, August 2019, Springer Science + Business Media

    Professor Zhi-Cheng JING

  33. Circulating Plasma Metabolomic Profiles Differentiate Rodent Models of Pulmonary Hypertension and Idiopathic Pulmonary Arterial Hypertension Patients

    Article • American Journal of Hypertension, July 2019, Oxford University Press (OUP)

    Professor Zhi-Cheng JING

  34. Antiphospholipid Syndrome in Chronic Thromboembolic Pulmonary Hypertension: A Well-Defined Subgroup of Patients

    Article • Thrombosis and Haemostasis, June 2019, Thieme Publishing Group

    Professor Zhi-Cheng JING

  35. Adventitial Cell Atlas of wt (Wild Type) and ApoE (Apolipoprotein E)-Deficient Mice Defined by Single-Cell RNA Sequencing

    Article • Arteriosclerosis Thrombosis and Vascular Biology, June 2019, Wolters Kluwer Health

    Professor Zhi-Cheng JING

  36. Monocrotaline pyrrole induces pulmonary endothelial damage through binding to and release from erythrocytes in lung during venous blood reoxygenation

    Article • AJP Lung Cellular and Molecular Physiology, May 2019, American Physiological Society

    Professor Zhi-Cheng JING

  37. Transthoracic Pulmonary Artery Denervation for Pulmonary Arterial Hypertension

    Article • Arteriosclerosis Thrombosis and Vascular Biology, April 2019, Wolters Kluwer Health

    Professor Zhi-Cheng JING

  38. Spermine on Endothelial Extracellular Vesicles Mediates Smoking-Induced Pulmonary Hypertension Partially Through Calcium-Sensing Receptor

    Article • Arteriosclerosis Thrombosis and Vascular Biology, March 2019, Wolters Kluwer Health

    Professor Zhi-Cheng JING

  39. Characteristics of cardiopulmonary exercise testing of patients with borderline mean pulmonary artery pressure

    Article • The Clinical Respiratory Journal, February 2019, Wiley

    Professor Zhi-Cheng JING

  40. Management and 1‐Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELD‐AF Registry

    Article • Journal of the American Heart Association, February 2019, Wolters Kluwer Health

    Professor Zhi-Cheng JING, Dr. Kenji Sadamatsu, Professor Dmitry Zateyshchikov, Filipa Costa

  41. Prevalence of antiphospholipid (aPL) antibodies among patients with chronic thromboembolic pulmonary hypertension: a systematic review and meta-analysis

    Article • Internal and Emergency Medicine, January 2019, Springer Science + Business Media

    Professor Zhi-Cheng JING

  42. Risk stratification and medical therapy of pulmonary arterial hypertension

    Article • European Respiratory Journal, January 2019, European Respiratory Society (ERS)

    Professor Nazzareno Galie, Prof Tomas Pulido, Professor Zhi-Cheng JING

  43. Germline BMP9 mutation causes idiopathic pulmonary arterial hypertension

    Article • European Respiratory Journal, December 2018, European Respiratory Society (ERS)

    Professor Zhi-Cheng JING

  44. 3-Bromopyruvate Attenuates Experimental Pulmonary Hypertension via Inhibition of Glycolysis

    Article • American Journal of Hypertension, December 2018, Oxford University Press (OUP)

    Professor Zhi-Cheng JING

  45. Percutaneous coronary intervention equates to placebo procedure in stable angina?

    Article • Journal of Thoracic Disease, December 2018, AME Publishing Company

    Professor Zhi-Cheng JING

  46. When REVEAL meets AMBITION, does it reveal more?

    Article • The Journal of Heart and Lung Transplantation, December 2018, Elsevier

    Professor Zhi-Cheng JING

  47. Increased risk of thrombosis in antiphospholipid syndrome patients treated with direct oral anticoagulants. Results from an international patient-level data meta-analysis

    Article • Autoimmunity Reviews, October 2018, Elsevier

    Professor Zhi-Cheng JING

  48. Epigenetic Dysregulation of the Dynamin-Related Protein 1 Binding Partners MiD49 and MiD51 Increases Mitotic Mitochondrial Fission and Promotes Pulmonary Arterial Hypertension

    Article • Circulation, July 2018, Wolters Kluwer Health

    Professor Allan Lawrie, Professor Zhi-Cheng JING

  49. Inhibition of CRTH2-mediated Th2 activation attenuates pulmonary hypertension in mice

    Article • The Journal of Experimental Medicine, July 2018, Rockefeller University Press

    Professor Zhi-Cheng JING

  50. Impact of Pituitary–Gonadal Axis Hormones on Pulmonary Arterial Hypertension in Men

    Article • Hypertension, July 2018, Wolters Kluwer Health

    Professor Zhi-Cheng JING

  51. Metabolic reprogramming of the urea cycle pathway in experimental pulmonary arterial hypertension rats induced by monocrotaline

    Article • May 2018, Springer Science + Business Media

    Professor Zhi-Cheng JING

  52. Efficacy and safety of bivalirudin in coronary artery disease patients with mild to moderate chronic kidney disease: Meta-analysis

    Article • Journal of Cardiology, May 2018, Elsevier

    Professor Zhi-Cheng JING

  53. IgG4-related disease of pulmonary artery causing pulmonary hypertension

    Article • Medicine, May 2018, Wolters Kluwer Health

    Professor Zhi-Cheng JING

  54. Whole-exome sequencing improves genetic testing accuracy in pulmonary artery hypertension

    Article • February 2018, SAGE Publications

    Professor Zhi-Cheng JING

  55. Prognostic Significance of Reduced Blood Pressure Response to Exercise in Pediatric Pulmonary Arterial Hypertension

    Article • American Review of Respiratory Disease, December 2017, American Thoracic Society

    Professor Zhi-Cheng JING, Professor Allan Lawrie

  56. Hemodynamic and gas exchange effects of inhaled iloprost in patients with COPD and pulmonary hypertension

    Article • International Journal of Chronic Obstructive Pulmonary Disease, November 2017, Dove Medical Press

    Professor Zhi-Cheng JING

  57. Hypermethylation of BMPR2 Promoter Occurs in Patients with Heritable Pulmonary Arterial Hypertension and Inhibits BMPR2 Expression

    Article • American Review of Respiratory Disease, October 2017, American Thoracic Society

    Professor Zhi-Cheng JING

  58. Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study

    Article • The Lancet Respiratory Medicine, October 2017, Elsevier

    Professor Zhi-Cheng JING

  59. Reply to “Comment on direct bilirubin as predictor of severity and mortality in idiopathic pulmonary arterial hypertension”

    Article • International Journal of Cardiology, July 2017, Elsevier

    Professor Zhi-Cheng JING

  60. Enhancing Insights into Pulmonary Vascular Disease through a Precision Medicine Approach. A Joint NHLBI–Cardiovascular Medical Research and Education Fund Workshop Report

    Article • American Journal of Respiratory and Critical Care Medicine, June 2017, American Thoracic Society

    Professor Zhi-Cheng JING

  61. A novel scoring index by Doppler echocardiography for predicting severe pulmonary hypertension due to chronic lung diseases: a cross-sectional diagnostic accuracy study

    Article • International Journal of Chronic Obstructive Pulmonary Disease, June 2017, Dove Medical Press

    Professor Zhi-Cheng JING

  62. Comparison of hemodynamic parameters in treatment-naïve and pre-treated patients with pulmonary arterial hypertension in the randomized phase III PATENT-1 study

    Article • The Journal of Heart and Lung Transplantation, May 2017, Elsevier

    Professor Zhi-Cheng JING

  63. Riociguat: a soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension

    Article • Drug Design Development and Therapy, April 2017, Dove Medical Press

    Professor Zhi-Cheng JING

  64. Efficacy of 1, 5, and 20 mg oral sildenafil in the treatment of adults with pulmonary arterial hypertension: a randomized, double-blind study with open-label extension

    Article • BMC Pulmonary Medicine, February 2017, Springer Science + Business Media

    Professor Zhi-Cheng JING

  65. Direct bilirubin: A new risk factor of adverse outcome in idiopathic pulmonary arterial hypertension

    Article • International Journal of Cardiology, February 2017, Elsevier

    Professor Zhi-Cheng JING

  66. Cysteine-rich 61 (Cyr61) upregulated in pulmonary arterial hypertension promotes the proliferation of pulmonary artery smooth muscle cells

    Article • International Journal of Medical Sciences, January 2017, Ivyspring International Publisher

    Professor Zhi-Cheng JING

  67. Cardiopulmonary exercise testing improves diagnostic specificity in patients with echocardiography-suspected pulmonary hypertension

    Article • Clinical Cardiology, November 2016, Wiley

    Professor Zhi-Cheng JING

  68. Elevated levels of plasma transforming growth factor-β1 in idiopathic and heritable pulmonary arterial hypertension

    Article • International Journal of Cardiology, November 2016, Elsevier

    Professor Zhi-Cheng JING

  69. Optical coherence tomography for hypertensive pulmonary vasculature

    Article • International Journal of Cardiology, November 2016, Elsevier

    Professor Zhi-Cheng JING

  70. Evaluation of efficacy, safety and tolerability of Ambrisentan in Chinese adults with pulmonary arterial hypertension: a prospective open label cohort study

    Article • BMC Cardiovascular Disorders, October 2016, Springer Science + Business Media

    Professor Zhi-Cheng JING

  71. Energetic Metabolic Roles in Pulmonary Arterial Hypertension and Right Ventricular Remodeling

    Article • Current Pharmaceutical Design, October 2016, Bentham Science Publishers

    Professor Zhi-Cheng JING

  72. Profiling nitric oxide metabolites in patients with idiopathic pulmonary arterial hypertension

    Article • European Respiratory Journal, September 2016, European Respiratory Society (ERS)

    Professor Zhi-Cheng JING

  73. Clinical characteristics of pulmonary hypertension in bronchiectasis

    Article • Frontiers of Medicine, September 2016, Springer Science + Business Media

    Professor Zhi-Cheng JING

  74. Elevated Levels of Circulating Bone Morphogenetic Protein 7 Predict Mortality in Pulmonary Arterial Hypertension

    Article • CHEST Journal, August 2016, Elsevier

    Professor Zhi-Cheng JING

  75. Identifying microRNAs targeting Wnt/β-catenin pathway in end-stage idiopathic pulmonary arterial hypertension

    Article • Journal of Molecular Medicine, May 2016, Springer Science + Business Media

    Professor Zhi-Cheng JING

  76. BMPR2 mutation is a potential predisposing genetic risk factor for congenital heart disease associated pulmonary vascular disease

    Article • International Journal of Cardiology, May 2016, Elsevier

    Professor Zhi-Cheng JING

  77. Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised, long-term extension trial

    Article • The Lancet Respiratory Medicine, May 2016, Elsevier

    Professor Zhi-Cheng JING

  78. Riociguat for the treatment of pulmonary hypertension: Chinese subgroup analyses and comparison

    Article • Heart Asia, May 2016, BMJ

    Professor Zhi-Cheng JING

  79. A global view of pulmonary hypertension

    Article • The Lancet Respiratory Medicine, April 2016, Elsevier

    Professor Rogerio Souza, Professor Zhi-Cheng JING

  80. Shape of the Pulmonary Artery Doppler-Flow Profile Predicts the Hemodynamics of Pulmonary Hypertension Caused by Left-Sided Heart Disease

    Article • Clinical Cardiology, March 2016, Wiley

    Professor Zhi-Cheng JING

  81. Acute Vasodilator Response in Pediatric Pulmonary Arterial Hypertension

    Article • Journal of the American College of Cardiology, March 2016, Elsevier

    Professor Zhi-Cheng JING

  82. Effect of intravenous l-carnitine in Chinese patients with chronic heart failure

    Article • European Heart Journal Supplements, February 2016, Oxford University Press (OUP)

    Professor Zhi-Cheng JING

  83. BMPR2 mutations and survival in pulmonary arterial hypertension: an individual participant data meta-analysis

    Article • The Lancet Respiratory Medicine, February 2016, Elsevier

    Professor Olivier SITBON, Dr. Erika Berman Rosenzweig, Professor Zhi-Cheng JING

  84. Reversal of right ventricular remodeling by dichloroacetate is related to inhibition of mitochondria-dependent apoptosis

    Article • Hypertension Research, January 2016, Springer Science + Business Media

    Professor Zhi-Cheng JING

  85. Review Common genetic risk factors of venous thromboembolism in Western and Asian populations

    Article • Genetics and Molecular Research, January 2016, Genetics and Molecular Research

    Professor Zhi-Cheng JING

  86. Haemodynamic characterisation and heart catheterisation complications in children with pulmonary hypertension: Insights from the Global TOPP Registry (tracking outcomes and practice in paediatric pulmonary hypertension)

    Article • International Journal of Cardiology, January 2016, Elsevier

    Professor Zhi-Cheng JING

  87. The limits of oral therapy in pulmonary arterial hypertension management

    Article • Therapeutics and Clinical Risk Management, November 2015, Taylor & Francis

    Professor Zhi-Cheng JING

  88. Research update for articles published in EJCI in 2013

    Article • European Journal of Clinical Investigation, September 2015, Wiley

    Professor Zhi-Cheng JING

  89. Effects of oral treatments on clinical outcomes in pulmonary arterial hypertension: A systematic review and meta-analysis

    Article • American Heart Journal, July 2015, Elsevier

    Professor Zhi-Cheng JING

  90. Intravenous fasudil improves in-hospital mortality of patients with right heart failure in severe pulmonary hypertension

    Article • Hypertension Research, March 2015, Springer Science + Business Media

    Professor Zhi-Cheng JING

  91. Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2)

    Article • European Respiratory Journal, January 2015, European Respiratory Society (ERS)

    Professor Zhi-Cheng JING

  92. Bosentan up-front or sequential add-on combination treatment for pulmonary arterial hypertension: long-term effects and prognosis

    Article • Academic Journal of Second Military Medical University, January 2015, China Science Publishing & Media Ltd.

    Professor Zhi-Cheng JING

  93. Isoprostane as a promising biomarker in pulmonary arterial hypertension: Preanalytical and analytical viewpoints. Response to letter to the editor

    Article • International Journal of Cardiology, December 2014, Elsevier

    Professor Zhi-Cheng JING

  94. Acute hemodynamic response of infused fasudil in patients with pulmonary arterial hypertension: A randomized, controlled, crossover study

    Article • International Journal of Cardiology, November 2014, Elsevier

    Professor Zhi-Cheng JING

  95. Frequency of Supraventricular Arrhythmias in Patients With Idiopathic Pulmonary Arterial Hypertension

    Article • The American Journal of Cardiology, November 2014, Elsevier

    Professor Zhi-Cheng JING

  96. Up-regulation of hexokinase1 in the right ventricle of monocrotaline induced pulmonary hypertension

    Article • October 2014, Springer Science + Business Media

    Professor Zhi-Cheng JING

  97. Plasma 15-F2t-isoprostane in idiopathic pulmonary arterial hypertension

    Article • International Journal of Cardiology, August 2014, Elsevier

    Professor Zhi-Cheng JING

  98. Connective tissue disease-associated pulmonary arterial hypertension in Chinese patients

    Article • European Respiratory Journal, May 2014, European Respiratory Society (ERS)

    Professor Zhi-Cheng JING

  99. BMPR2 Germline Mutation in Chronic Thromboembolic Pulmonary Hypertension

    Article • Lung, April 2014, Springer Science + Business Media

    Professor Zhi-Cheng JING

  100. Rivaroxaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies

    Article • Thrombosis Journal, December 2013, Springer Science + Business Media

    Professor Zhi-Cheng JING

  101. Updated Treatment Algorithm of Pulmonary Arterial Hypertension

    Article • Journal of the American College of Cardiology, December 2013, Elsevier

    Professor Zhi-Cheng JING

  102. Pediatric Pulmonary Arterial Hypertension

    Article • Current Hypertension Reports, October 2013, Springer Science + Business Media

    Professor Zhi-Cheng JING

  103. Epidemiology of Pulmonary Arterial Hypertension

    Article • Current Hypertension Reports, October 2013, Springer Science + Business Media

    Professor Zhi-Cheng JING

  104. Oral Treprostinil for the Treatment of Pulmonary Arterial Hypertension in Patients Receiving Background Endothelin Receptor Antagonist and Phosphodiesterase Type 5 Inhibitor Therapy (The FREEDOM-C2 Study)

    Article • CHEST Journal, September 2013, Elsevier

    Professor Zhi-Cheng JING

  105. Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension

    Article • New England Journal of Medicine, August 2013, New England Journal of Medicine (NEJM/MMS)

    Professor Rogerio Souza, Professor Olivier SITBON, Professor Zhi-Cheng JING

  106. Antioxidant effects of phosphodiesterase-5 inhibitors: reply

    Article • Cardiovascular Research, August 2013, European Society of Cardiology

    Professor Zhi-Cheng JING

  107. Clinical and genetic characteristics of Chinese patients with hereditary haemorrhagic telangiectasia-associated pulmonary hypertension

    Article • European Journal of Clinical Investigation, August 2013, Wiley

    Professor Zhi-Cheng JING

  108. Riociguat for the Treatment of Pulmonary Arterial Hypertension

    Article • New England Journal of Medicine, July 2013, New England Journal of Medicine (NEJM/MMS)

    Horst Olschewski, Professor Zhi-Cheng JING

  109. Complexities of oestradiol pharmacology in pulmonary arterial hypertension

    Article • European Respiratory Journal, May 2013, European Respiratory Society (ERS)

    Professor Zhi-Cheng JING

  110. The phosphodiesterase-5 inhibitor vardenafil reduces oxidative stress while reversing pulmonary arterial hypertension

    Article • Cardiovascular Research, May 2013, European Society of Cardiology

    Professor Zhi-Cheng JING

  111. Efficacy and Safety of Oral Treprostinil Monotherapy for the Treatment of Pulmonary Arterial Hypertension

    Article • Circulation, February 2013, Wolters Kluwer Health

    Professor Zhi-Cheng JING

  112. Lower Socioeconomic Status Is Associated with Worse Outcomes in Pulmonary Arterial Hypertension

    Article • American Journal of Respiratory and Critical Care Medicine, February 2013, American Thoracic Society

    Professor Zhi-Cheng JING

  113. BMPR2Mutations Influence Phenotype More Obviously in Male Patients With Pulmonary Arterial Hypertension

    Article • Circulation Cardiovascular Genetics, October 2012, Wolters Kluwer Health

    Professor Zhi-Cheng JING

  114. Oestradiol ameliorates monocrotaline pulmonary hypertensionviaNO, prostacyclin and endothelin-1 pathways

    Article • European Respiratory Journal, August 2012, European Respiratory Society (ERS)

    Professor Zhi-Cheng JING

  115. Serum High-Density Lipoprotein Cholesterol Levels as a Prognostic Indicator in Patients With Idiopathic Pulmonary Arterial Hypertension

    Article • The American Journal of Cardiology, August 2012, Elsevier

    Professor Zhi-Cheng JING

  116. Usefulness of Intravenous Adenosine in Idiopathic Pulmonary Arterial Hypertension as a Screening Agent for Identifying Long-Term Responders to Calcium Channel Blockers

    Article • The American Journal of Cardiology, June 2012, Elsevier

    Professor Zhi-Cheng JING

  117. Clinical features of paediatric pulmonary hypertension: a registry study

    Article • The Lancet, February 2012, Elsevier

    Professor Damien Bonnet, Professor Zhi-Cheng JING, Rolf Berger

  118. Prolonged QRS Duration

    Article • CHEST Journal, February 2012, Elsevier

    Professor Zhi-Cheng JING

  119. High-Altitude Pulmonary Hypertension

    Article • January 2012, Karger Publishers

    Professor Zhi-Cheng JING

  120. Idiopathic Pulmonary Arterial Hypertension and Its Prognosis in the Modern Management Era in Developed and Developing Countries

    Article • January 2012, Karger Publishers

    Professor Zhi-Cheng JING

  121. MicroRNA-134 as a potential plasma biomarker for the diagnosis of acute pulmonary embolism

    Article • Journal of Translational Medicine, September 2011, Springer Science + Business Media

    Professor Zhi-Cheng JING

  122. Oral sildenafil treatment for Eisenmenger syndrome: a prospective, open-label, multicentre study

    Article • Heart, September 2011, BMJ

    Professor Zhi-Cheng JING

  123. Survival of Chinese Patients With Pulmonary Arterial Hypertension in the Modern Treatment Era

    Article • CHEST Journal, August 2011, Elsevier

    Professor Zhi-Cheng JING

  124. Molecular genetics and clinical features of Chinese idiopathic and heritable pulmonary arterial hypertension patients

    Article • European Respiratory Journal, July 2011, European Respiratory Society (ERS)

    Professor Zhi-Cheng JING

  125. Vardenafil in Pulmonary Arterial Hypertension

    Article • American Journal of Respiratory and Critical Care Medicine, June 2011, American Thoracic Society

    Professor Zhi-Cheng JING

  126. Iloprost—different indications and different national experiences in treating pulmonary hypertension

    Article • Clinical Research in Cardiology Supplements, September 2010, Springer Science + Business Media

    Professor Zhi-Cheng JING

  127. Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension

    Article • European Respiratory Journal, June 2010, European Respiratory Society (ERS)

    Professor Rogerio Souza, Professor Olivier SITBON, Professor Zhi-Cheng JING

  128. Efficacy, safety and tolerability of bosentan in Chinese patients with pulmonary arterial hypertension

    Article • The Journal of Heart and Lung Transplantation, February 2010, Elsevier

    Professor Zhi-Cheng JING

  129. Pulmonary function testing in patients with pulmonary arterial hypertension

    Article • Respiratory Medicine, August 2009, Elsevier

    Professor Zhi-Cheng JING

  130. The efficacy and safety of sildenafil in Chinese patients with pulmonary arterial hypertension

    Article • Hypertension Research, July 2009, Springer Science + Business Media

    Professor Zhi-Cheng JING

  131. Vardenafil treatment for patients with pulmonary arterial hypertension: a multicentre, open-label study

    Article • Heart, June 2009, BMJ

    Professor Zhi-Cheng JING

  132. Updated Clinical Classification of Pulmonary Hypertension

    Article • Journal of the American College of Cardiology, June 2009, Elsevier

    Professor Rogerio Souza, Professor Zhi-Cheng JING

  133. High-altitude pulmonary hypertension

    Article • European Respiratory Review, March 2009, European Respiratory Society (ERS)

    Professor Zhi-Cheng JING

  134. Iloprost for pulmonary vasodilator testing in idiopathic pulmonary arterial hypertension

    Article • European Respiratory Journal, February 2009, European Respiratory Society (ERS)

    Professor Zhi-Cheng JING

  135. Hemodynamic variables and clinical features correlated with serum uric acid in patients with pulmonary arterial hypertension

    Article • Chinese Medical Journal, December 2008, Wolters Kluwer Health

    Professor Zhi-Cheng JING

  136. Registry and Survival Study in Chinese Patients With Idiopathic and Familial Pulmonary Arterial Hypertension

    Article • CHEST Journal, August 2007, Elsevier

    Professor Zhi-Cheng JING

  137. Post-infarction treatment with simvastatin reduces myocardial no-reflow by opening of the KATPchannel

    Article • European Journal of Heart Failure, January 2007, Wiley

    Professor Zhi-Cheng JING

  138. Complications of Right Heart Catheterization Procedures in Patients With Pulmonary Hypertension in Experienced Centers

    Article • Journal of the American College of Cardiology, December 2006, Elsevier

    Professor Zhi-Cheng JING

  139. Different effects of tirofiban and aspirin plus clopidogrel on myocardial no-reflow in a mini-swine model of acute myocardial infarction and reperfusion

    Article • Heart, August 2006, BMJ

    Professor Zhi-Cheng JING

  140. Pretreatment with fosinopril or valsartan reduces myocardial no-reflow after acute myocardial infarction and reperfusion

    Article • Coronary Artery Disease, August 2006, Wolters Kluwer Health

    Professor Zhi-Cheng JING

  141. Herpes Simplex Virus Type 2 Infection Is a Risk Factor for Hypertension

    Article • Hypertension Research, January 2004, Japanese Society of Hypertension

    Professor Zhi-Cheng JING